SITC 2021 | STING agonists for cancer therapy

Jason Luke, MD, FACP, UPMC Hillman Cancer Center, Pittsburgh, PA, talks on advances in cGAS/stimulator of interferon genes (STING) agonists for cancer therapy. Early clinical data has not provided benefit which was assumed based on preclinical animal models. Dr. Luke describes the limitations to next-generation STING including the need to inject the medicine directly into the tumor, identifying which immune cells are required to activate to elicit an antitumor response and the identification of patients who are most likely to benefit. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.